E V Mccloskey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7265771/publications.pdf

Version: 2024-02-01

		1893	2280
486	45,907	102	200
papers	citations	h-index	g-index

505	505	505	25812
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The application of FRAX in Ecuador. Revista Colombiana De ReumatologÃa, 2023, 30, 199-206.	0.1	2
2	Fracture risk assessment by the FRAX model. Climacteric, 2022, 25, 22-28.	2.4	20
3	Osteoporosis and fractures in women: the burden of disease. Climacteric, 2022, 25, 4-10.	2.4	71
4	FRAX-based intervention thresholds for Pakistan. Osteoporosis International, 2022, 33, 105-112.	3.1	1
5	One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. Osteoporosis International, 2022, 33, 185-194.	3.1	8
6	Prediction of imminent fracture risk in Canadian women and men aged 45Âyears or older: external validation of the Fracture Risk Evaluation Model (FREM). Osteoporosis International, 2022, 33, 57-66.	3.1	10
7	Osteoporosis in Europe: a compendium of country-specific reports. Archives of Osteoporosis, 2022, 17, 23.	2.4	66
8	Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 2022, 17, 12.	2.4	5
9	Prevalence of FRAX risk factors and the osteoporosis treatment gap among womenâ€‰â‰¥â€‰70Âyears of age in routine primary care across 8 countries in Europe. Archives of Osteoporosis, 2022, 17, 20.	2.4	3
10	FRAX. , 2022, , 89-99.		1
11	Digital health interventions for osteoporosis and post-fragility fracture care. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210835.	2.7	6
12	FREM predicts 10-year incident fracture risk independent of FRAXÂ® probability: a registry-based cohort study. Osteoporosis International, 2022, , 1.	3.1	1
13	Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporosis International, 2022, 33, 1185-1189.	3.1	6
14	Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Archives of Osteoporosis, 2022, 17, 49.	2.4	4
15	UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 2022, 17, 58.	2.4	146
16	Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Archives of Osteoporosis, 2022, 17, 56.	2.4	6
17	Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporosis International, 2022, 33, 1725-1738.	3.1	13
18	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.1	33

#	Article	IF	Citations
19	Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Network Open, 2022, 5, e2215396.	5.9	17
20	Trabecular Bone Score Adjustment for the Fracture Risk Assessment Tool (FRAXÂ®). Calcified Tissue International, 2022, 111, 226-227.	3.1	2
21	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 2022, 17, .	2.4	13
22	Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probabilityâ€"results from the Womenâ€™s Health Initiative hormone therapy trials. Osteoporosis International, 2022, 33, 2297-2305.	3.1	9
23	Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. Osteoporosis International, 2021, 32, 165-171.	3.1	6
24	Fracture risk assessment in celiac disease: a registry-based cohort study. Osteoporosis International, 2021, 32, 93-99.	3.1	11
25	Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporosis International, 2021, 32, 39-46.	3.1	26
26	The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporosis International, 2021, 32, 75-84.	3.1	28
27	Transmission of whole body vibration â€“ Comparison of three vibration platforms in healthy subjects. Bone, 2021, 144, 115802.	2.9	7
28	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporosis International, 2021, 32, 817-829.	3.1	21
29	The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporosis International, 2021, 32, 47-54.	3.1	21
30	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.6	132
31	Clodronate. Bone, 2021, 143, 115715.	2.9	13
32	Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. Osteoporosis International, 2021, 32, 113-122.	3.1	18
33	The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporosis International, 2021, 32, 251-259.	3.1	75
34	Increased development of radiographic hip osteoarthritis in individuals with high bone mass: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 4.	3.5	9
35	A surrogate FRAX model for Pakistan. Archives of Osteoporosis, 2021, 16, 34.	2.4	5
36	Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporosis International, 2021, 32, 1601-1608.	3.1	15

#	Article	IF	Citations
37	Epidemiology of hip fracture in Botswana. Archives of Osteoporosis, 2021, 16, 24.	2.4	12
38	The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporosis International, 2021, 32, 1547-1555.	3.1	24
39	Femoral neck strain prediction during level walking using a combined musculoskeletal and finite element model approach. PLoS ONE, 2021, 16, e0245121.	2.5	11
40	Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Medicine, 2021, 13, 16.	8.2	35
41	FRAX-based fracture probabilities in South Africa. Archives of Osteoporosis, 2021, 16, 51.	2.4	10
42	Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporosis International, 2021, 32, 1973-1979.	3.1	5
43	Use of an electronic medical record dashboard to identify gaps in osteoporosis care. Archives of Osteoporosis, 2021, 16, 76.	2.4	3
44	Short time horizons for fracture prediction tools: time for a rethink. Osteoporosis International, 2021, 32, 1019-1025.	3.1	14
45	An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporosis International, 2021, 32, 1951-1960.	3.1	38
46	FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. Journal of Osteoporosis, 2021, 2021, 1-7.	0.5	2
47	FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 2021, 16, 87.	2.4	11
48	SCOPE 2021: a new scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2021, 16, 82.	2.4	233
49	A country-specific FRAX model for Botswana. Archives of Osteoporosis, 2021, 16, 90.	2.4	4
50	The application of FRAX in Saudi Arabia. Archives of Osteoporosis, 2021, 16, 166.	2.4	6
51	Systematic screening using FRAXÂ® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporosis International, 2020, 31, 67-75.	3.1	25
52	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1-12.	3.1	220
53	Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care, 2020, 43, 137-144.	8.6	82
54	Reassessment Intervals for Transition From Low to High Fracture Risk Among Adults Older Than 50 Years. JAMA Network Open, 2020, 3, e1918954.	5.9	6

#	Article	IF	Citations
55	The effect of bisphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone, 2020, 131, 115158.	2.9	14
56	Incidence of myocardial infarction and associated mortality varies by latitude and season: findings from a Swedish Registry Study. Journal of Public Health, 2020, 42, e440-e448.	1.8	2
57	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. Bone Reports, 2020, 13, 100729.	0.4	14
58	Personalized estimation of one-year mortality risk after elective hip or knee arthroplasty for osteoarthritis. Bone and Joint Research, 2020, 9, 808-820.	3.6	3
59	Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. Archives of Osteoporosis, 2020, 15, 119.	2.4	7
60	Use of age-dependent FRAX-based intervention thresholds for Singapore. Archives of Osteoporosis, 2020, 15, 104.	2.4	14
61	JointCalc: A web-based personalised patient decision support tool for joint replacement. International Journal of Medical Informatics, 2020, 142, 104217.	3.3	12
62	FRAX and ethnicity. Osteoporosis International, 2020, 31, 2063-2067.	3.1	12
63	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion, 2020, 36, 1861-1872.	1.9	12
64	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	7.4	180
65	Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2487-2506.	3.6	35
66	Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporosis International, 2020, 31, 1059-1067.	3.1	52
67	Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporosis International, 2020, 31, 1817-1828.	3.1	53
68	Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. PLoS Medicine, 2020, 17, e1003152.	8.4	45
69	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. Osteoporosis International, 2020, 31, 2271-2286.	3.1	76
70	A surrogate FRAX model for the Kyrgyz Republic. Archives of Osteoporosis, 2020, 15, 68.	2.4	6
71	Loss in DXA-estimated total body lean mass but not fat mass predicts incident major osteoporotic fracture and hip fracture independently from FRAX: a registry-based cohort study. Archives of Osteoporosis, 2020, 15, 96.	2.4	17
72	Epidemiology of osteoporotic fracture in Kazakhstan and development of a country specific FRAX model. Archives of Osteoporosis, 2020, 15, 30.	2.4	21

#	Article	IF	Citations
73	Epidemiology of hip fractures in Bulgaria: development of a country-specific FRAX model. Archives of Osteoporosis, 2020, 15, 28.	2.4	4
74	A decade of FRAX: how has it changed the management of osteoporosis?. Aging Clinical and Experimental Research, 2020, 32, 187-196.	2.9	83
75	Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporosis International, 2020, 31, 457-464.	3.1	5
76	A Pooled Analysis of Fall Incidence From Placeboâ€Controlled Trials of Denosumab. Journal of Bone and Mineral Research, 2020, 35, 1014-1021.	2.8	21
77	Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporosis International, 2020, 31, 1499-1506.	3.1	17
78	Screening for high fracture risk. Osteoporosis International, 2020, 31, 1179-1180.	3.1	1
79	Fragility fractures in Europe: burden, management and opportunities. Archives of Osteoporosis, 2020, 15, 59.	2.4	369
80	Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nature Reviews Endocrinology, 2020, 16, 437-447.	9.6	237
81	Sarcopenia Definitions as Predictors of Fracture Risk Independent of FRAXÂ®, Falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A Meta-Analysis. Journal of Bone and Mineral Research, 2020, 36, 1235-1244.	2.8	33
82	Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). Journal of Bone and Mineral Research, 2020, 36, 654-661.	2.8	18
83	Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study. Osteoporosis International, 2020, 31, 1079-1087.	3.1	16
84	Epidemiology of osteoporotic fracture in Moldova and development of a country-specific FRAX model. Archives of Osteoporosis, 2020, 15, 13.	2.4	20
85	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 2020, 25, 100311.	2.4	27
86	Individuals with high bone mass have increased progression of radiographic and clinical features of knee osteoarthritis. Osteoarthritis and Cartilage, 2020, 28, 1180-1190.	1.3	13
87	MRI-based anatomical characterisation of lower-limb muscles in older women. PLoS ONE, 2020, 15, e0242973.	2.5	11
88	Deep Learning With Electronic Health Records for Short-Term Fracture Risk Identification: Crystal Bone Algorithm Development and Validation. Journal of Medical Internet Research, 2020, 22, e22550.	4.3	25
89	The Effect of Fracture Recency on Observed 10-Year Fracture Probability: A Registry-Based Cohort Study. Journal of Bone and Mineral Research, 2020, 37, 848-855.	2.8	9
90	Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate. Journal of Bone and Mineral Research, 2020, 37, 1117-1124.	2.8	2

#	Article	IF	Citations
91	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
92	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
93	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
94	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
95	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
96	MRI-based anatomical characterisation of lower-limb muscles in older women. , 2020, 15, e0242973.		0
97	Quantitating Age-Related BMD Textural Variation from DXA Region-Free-Analysis: A Study of Hip Fracture Prediction in Three Cohorts. Journal of Bone and Mineral Research, 2020, 37, 1679-1688.	2.8	3
98	Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporosis International, 2019, 30, 2195-2203.	3.1	24
99	FRAX-based intervention and assessment thresholds for osteoporosis in Iran. Osteoporosis International, 2019, 30, 2225-2230.	3.1	4
100	Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. Archives of Osteoporosis, 2019, 14, 93.	2.4	13
101	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. Oncologist, 2019, 24, 1432-1438.	3.7	10
102	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone, 2019, 127, 401-418.	2.9	33
103	Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporosis International, 2019, 30, 1745-1754.	3.1	15
104	Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. Annals of Oncology, 2019, 30, v334-v335.	1.2	0
105	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
106	Temporal changes in access to FRAXÂ® in Thailand between 2010 and 2018. Archives of Osteoporosis, 2019, 14, 66.	2.4	10
107	Fracture risk following intermission of osteoporosis therapy. Osteoporosis International, 2019, 30, 1733-1743.	3.1	38
108	Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. Journal of Bone and Mineral Research, 2019, 34, 1428-1435.	2.8	52

#	Article	IF	Citations
109	Estimating patient-specific mortality after joint replacement: algorithm development and validation using national audit datasets. Osteoarthritis and Cartilage, 2019, 27, S229.	1.3	1
110	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 2019, 105, 109-124.	3.1	51
111	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 2019, 105, 1-14.	3.1	295
112	Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Archives of Osteoporosis, 2019, 14, 15.	2.4	11
113	Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporosis International, 2019, 30, 525-526.	3.1	3
114	Appendicular lean mass and fracture risk assessment: implications for FRAXÂ® and sarcopenia. Osteoporosis International, 2019, 30, 537-539.	3.1	17
115	Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporosis International, 2019, 30, 917-922.	3.1	26
116	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
117	The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. Journal of Bone and Mineral Research, 2018, 33, 845-851.	2.8	58
118	Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fracturesâ€"A Post Hoc Analysis of the SCOOP Study. Journal of Bone and Mineral Research, 2018, 33, 1020-1026.	2.8	45
119	Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. Archives of Osteoporosis, 2018, 13, 42.	2.4	16
120	Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1302-1309.	3.6	19
121	Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. Osteoporosis International, 2018, 29, 751-758.	3.1	37
122	Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. Osteoporosis International, 2018, 29, 759-767.	3.1	15
123	Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 269-278.	7.3	482
124	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Quality of Life Research, 2018, 27, 707-716.	3.1	36
125	Low risk for hip fracture and high risk for hip arthroplasty due to osteoarthritis among Swedish farmers. Osteoporosis International, 2018, 29, 741-749.	3.1	11
126	Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporosis International, 2018, 29, 1367-1378.	3.1	18

#	Article	IF	Citations
127	Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study. Bone, 2018, 110, 386-391.	2.9	11
128	Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporosis International, 2018, 29, 1407-1417.	3.1	40
129	Validation of calcaneus trabecular microstructure measurements by HR-pQCT. Bone, 2018, 106, 69-77.	2.9	18
130	Quality of life for up to 18Âmonths after low-energy hip, vertebral, and distal forearm fracturesâ€"results from the ICUROS. Osteoporosis International, 2018, 29, 557-566.	3.1	88
131	Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet, The, 2018, 391, 741-747.	13.7	206
132	Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2018, 33, 510-516.	2.8	61
133	FRAXÂ® based intervention thresholds for management of osteoporosis in Singaporean women. Archives of Osteoporosis, 2018, 13, 130.	2.4	18
134	A closer look at SCOOP: screening for fracture prevention â€“ Authors' reply. Lancet, The, 2018, 392, 552-553.	13.7	0
135	A brief history of FRAX. Archives of Osteoporosis, 2018, 13, 118.	2.4	144
136	Towards a toolkit for the assessment and monitoring of musculoskeletal ageing. Age and Ageing, 2018, 47, 774-777.	1.6	1
137	In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. Bone, 2018, 113, 161-168.	2.9	41
138	Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. Journal of Bone and Mineral Research, 2018, 33, 1923-1930.	2.8	104
139	Epidemiology of Hip Fractures in Two Regions of Ukraine. Journal of Osteoporosis, 2018, 2018, 1-6.	0.5	9
140	Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2018, 33, 2150-2157.	2.8	81
141	Comparison of HR-pQCT- and microCT-based finite element models for the estimation of the mechanical properties of the calcaneus trabecular bone. Biomechanics and Modeling in Mechanobiology, 2018, 17, 1715-1730.	2.8	12
142	The Authors reply: â€œDual energy Xâ€ray absorptiometry: gold standard for muscle mass?â€•by Scafoglieri et al.. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 788-790.	7.3	3
143	Estimating an Individualâ€™s Probability of Revision Surgery After Knee Replacement: A Comparison of Modeling Approaches Using a National Data Set. American Journal of Epidemiology, 2018, 187, 2252-2262.	3.4	18
144	Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). Osteoporosis International, 2018, 29, 1511-1513.	3.1	18

#	Article	IF	Citations
145	Characteristics of recurrent fractures. Osteoporosis International, 2018, 29, 1747-1757.	3.1	122
146	Establishing and evaluating FRAX Â® probability thresholds in Taiwan. Journal of the Formosan Medical Association, 2017, 116, 161-168.	1.7	16
147	Imminent risk of fracture after fracture. Osteoporosis International, 2017, 28, 775-780.	3.1	275
148	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 2017, 28, 1507-1529.	3.1	160
149	Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. JAMA Psychiatry, 2017, 74, 641.	11.0	60
150	UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 2017, 12, 43.	2.4	609
151	The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. Journal of Bone and Mineral Research, 2017, 32, 1625-1631.	2.8	40
152	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.1	126
153	FRAX for fracture prediction shorter and longer than 10Âyears: the Manitoba BMD registry. Osteoporosis International, 2017, 28, 2557-2564.	3.1	19
154	The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review. Bone, 2017, 99, 39-46.	2.9	14
155	Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. Journal of Bone and Mineral Research, 2017, 32, 1568-1574.	2.8	52
156	Total Hip Bone Area Affects Fracture Prediction With FRAXÂ® in Canadian White Women. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4242-4249.	3.6	7
157	Overview of Fracture Prediction Tools. Journal of Clinical Densitometry, 2017, 20, 444-450.	1.2	62
158	FRAX Update. Journal of Clinical Densitometry, 2017, 20, 360-367.	1.2	81
159	FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporosis International, 2017, 28, 3099-3105.	3.1	42
160	Bisphosphonates in osteoporosis: NICE and easy?. Lancet, The, 2017, 390, 2243-2244.	13.7	23
161	Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate. Archives of Osteoporosis, 2017, 12, 98.	2.4	24
162	Identification of vertebral fractures: a moderately severe solution?. Osteoporosis International, 2017, 28, 1853-1855.	3.1	1

#	Article	IF	Citations
163	Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UKâ€"an analysis of anonymous website activity. Osteoporosis International, 2017, 28, 71-76.	3.1	15
164	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. Journal of Bone and Mineral Research, 2016, 31, 940-948.	2.8	508
165	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 2016, 7, 243-246.	2.8	90
166	Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4489-4496.	3.6	92
167	Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. Journal of Bone and Mineral Research, 2016, 31, 640-649.	2.8	38
168	A systematic review of intervention thresholds based on FRAX. Archives of Osteoporosis, 2016, 11, 25.	2.4	317
169	The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone, 2016, 92, 94-99.	2.9	25
170	Automatic Quality Control for Population Imaging: A Generic Unsupervised Approach. Lecture Notes in Computer Science, 2016, , 291-299.	1.3	3
171	Direct comparison of FRAXR and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. Osteoporosis International, 2016, 27, 2689-2695.	3.1	15
172	FRAX updates 2016. Current Opinion in Rheumatology, 2016, 28, 433-441.	4.3	37
173	Bone turnover markers: response to comments by Seeman and Nguyen. Osteoporosis International, 2016, 27, 37-37.	3.1	0
174	Use of FRAXÂ® in men. Joint Bone Spine, 2016, 83, 477-478.	1.6	3
175	Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 2016, 27, 21-31.	3.1	126
176	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	2.9	22
177	SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. Calcified Tissue International, 2016, 98, 417-425.	3.1	32
178	FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporosis International, 2016, 27, 267-274.	3.1	41
179	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
180	Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. Journal of Clinical Densitometry, 2016, 19, 326-331.	1.2	46

#	Article	IF	Citations
181	A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporosis International, 2016, 27, 417-419.	3.1	15
182	Intervention Thresholds and the Diagnosis of Osteoporosis. Journal of Bone and Mineral Research, 2015, 30, 1747-1753.	2.8	100
183	Can we treat to target in osteoporosis?. International Journal of Clinical Rheumatology, 2015, 10, 1-4.	0.3	4
184	Unilateral compressive optic neuropathy due to skull hyperostosis secondary to nutritional vitamin A deficiency. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 75-7.	1.0	8
185	Burden of high fracture probability worldwide: secular increases 2010â€“2040. Osteoporosis International, 2015, 26, 2243-2248.	3.1	382
186	CORRIGENDA. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3219-3219.	3.6	16
187	Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. Osteoporosis International, 2015, 26, 1979-1987.	3.1	74
188	Magnitude of fragility fracture risk in the very oldâ€”are we meeting their needs? The Newcastle 85+ Study. Osteoporosis International, 2015, 26, 123-130.	3.1	11
189	Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone, 2015, 78, 216-224.	2.9	362
190	FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporosis International, 2015, 26, 2677-2684.	3.1	35
191	Adjusting Fracture Probability by Trabecular Bone Score. Calcified Tissue International, 2015, 96, 500-509.	3.1	155
192	Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporosis International, 2015, 26, 2347-2353.	3.1	34
193	FRAX-based assessment and intervention thresholdsâ€”an exploration of thresholds in women aged 50Âyears and older in the UK. Osteoporosis International, 2015, 26, 2091-2099.	3.1	56
194	Is the Swedish FRAX model appropriate for Swedish immigrants?. Osteoporosis International, 2015, 26, 2617-2622.	3.1	32
195	FRAX and fracture prediction without bone mineral density. Climacteric, 2015, 18, 2-9.	2.4	58
196	Hip Axis Length Is a FRAX- and Bone Density-Independent Risk Factor for Hip Fracture in Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2063-2070.	3.6	48
197	Incidence of hip fracture in Brazil and the development of a FRAX model. Archives of Osteoporosis, 2015, 10, 224.	2.4	66
198	Epidemiological Burden of Postmenopausal Osteoporosis in Italy from 2010 to 2020: Estimations from a Disease Model. Calcified Tissue International, 2014, 95, 419-427.	3.1	20

#	Article	IF	Citations
199	Pre-screening young postmenopausal women for BMD testing. BoneKEy Reports, 2014, 3, 544.	2.7	2
200	The Effect of Latitude on the Risk and Seasonal Variation in Hip Fracture in Sweden. Journal of Bone and Mineral Research, 2014, 29, 2217-2223.	2.8	44
201	Can Change in FRAX Score Be Used to â€œTreat to Targetâ€? A Population-Based Cohort Study. Journal of Bone and Mineral Research, 2014, 29, 1074-1080.	2.8	27
202	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Human Molecular Genetics, 2014, 23, 3054-3068.	2.9	90
203	Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts. Calcified Tissue International, 2014, 95, 428-435.	3.1	52
204	Genome-wide association study for radiographic vertebral fractures: A potential role for the 16q24 BMD locus. Bone, 2014, 59, 20-27.	2.9	32
205	Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporosis International, 2014, 25, 251-263.	3.1	60
206	Worldwide uptake of FRAX. Archives of Osteoporosis, 2014, 9, 166.	2.4	95
207	FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporosis International, 2014, 25, 61-69.	3.1	28
208	Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporosis International, 2014, 25, 235-241.	3.1	60
209	Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture. Journal of Bone and Mineral Research, 2014, 29, 2511-2519.	2.8	74
210	Evaluation of the FRAX Model for Hip Fracture Predictions in the Population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE). Calcified Tissue International, 2014, 95, 39-45.	3.1	15
211	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Human Molecular Genetics, 2014, 23, 1923-1933.	2.9	130
212	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. Journal of Bone and Mineral Research, 2014, 29, 518-530.	2.8	617
213	The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporosis International, 2014, 25, 2445-2451.	3.1	29
214	Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 2014, 25, 2533-2543.	3.1	61
215	Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 2014, 25, 2729-2741.	3.1	49
216	Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. Osteoporosis International, 2014, 25, 1831-1836.	3.1	15

#	Article	IF	Citations
217	Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporosis International, 2014, 25, 2271-2277.	3.1	101
218	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. Calcified Tissue International, 2014, 94, 560-567.	3.1	141
219	Consensus of Official Position of IOF/ISCD FRAX Initiatives in Asia-Pacific Region. Journal of Clinical Densitometry, 2014, 17, 150-155.	1.2	19
220	The Osteoporosis Treatment Gap. Journal of Bone and Mineral Research, 2014, 29, 1926-1928.	2.8	122
221	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. Journal of Bone and Mineral Research, 2014, 29, 223-233.	2.8	388
222	Resource Use Related To Vertebral Fractures Based On Data From Icuros. Value in Health, 2014, 17, A48-A49.	0.3	0
223	EPIDEMIOLOGY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN FEDERATION AND THE RUSSIAN MODEL OF FRAX. Osteoporosis and Bone Diseases, 2014, 17, 3-8.	1.4	9
224	Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. Bone, 2014, 59, 20-7.	2.9	17
225	Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model. Calcified Tissue International, 2013, 92, 429-436.	3.1	38
226	Assessing the Impact of Osteoporosis on the Burden of Hip Fractures. Calcified Tissue International, 2013, 92, 42-49.	3.1	104
227	Fracture Risk Assessment. , 2013, , 1611-1637.		5
228	Direct comparison of eight national FRAXÂ® tools for fracture prediction and treatment qualification in Canadian women. Archives of Osteoporosis, 2013, 8, 145.	2.4	24
229	FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Archives of Osteoporosis, 2013, 8, 164.	2.4	11
230	Osteoporosis in the European Union: a compendium of country-specific reports. Archives of Osteoporosis, 2013, 8, 137.	2.4	561
231	Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of Osteoporosis, 2013, 8, 136.	2.4	1,932
232	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.4	125
233	Pitfalls in the external validation of FRAX: response to Bolland et al.. Osteoporosis International, 2013, 24, 391-392.	3.1	5
234	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2013, 24, 23-57.	3.1	1,560

#	Article	IF	Citations
235	Treatment of osteoporosis in men. Bone, 2013, 53, 134-144.	2.9	84
236	Can we improve the prediction of hip fracture by assessing bone structure using shape and appearance modelling?. Bone, 2013, 53, 188-193.	2.9	40
237	Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 2013, 75, 392-396.	2.4	264
238	Screening for chronic comorbid diseases in people with <scp>HIV</scp>: the need for a strategic approach. HIV Medicine, 2013, 14, 1-11.	2.2	27
239	Selection of Women Aged 50â€“64 Yr for Bone Density Measurement. Journal of Clinical Densitometry, 2013, 16, 570-578.	1.2	18
240	Analysis of Body Composition in Individuals With High Bone Mass Reveals a Marked Increase in Fat Mass in Women But Not Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 818-828.	3.6	29
241	The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)â€”quality of life during the first 4Âmonths after fracture. Osteoporosis International, 2013, 24, 811-823.	3.1	114
242	A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3Âyears. Rheumatology International, 2013, 33, 2231-2239.	3.0	29
243	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 2013, 28, 1007-1013.	2.8	27
244	Goal-directed therapy in osteoporosis. Journal of Bone and Mineral Research, 2013, 28, 439-441.	2.8	13
245	Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. Journal of Bone and Mineral Research, 2013, 28, 1014-1021.	2.8	78
246	WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genetics, 2012, 8, e1002745.	3.5	240
247	FRAX updates 2012. Current Opinion in Rheumatology, 2012, 24, 554-560.	4.3	43
248	High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. Journal of Bone and Mineral Research, 2012, 27, 1390-1396.	2.8	49
249	A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporosis International, 2012, 23, 2507-2515.	3.1	51
250	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 2012, 23, 2257-2276.	3.1	291
251	A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International, 2012, 23, 2239-2256.	3.1	1,048
252	Variations in latitude may or may not explain the worldwide variation in hip fracture incidence. Osteoporosis International, 2012, 23, 2401-2402.	3.1	3

#	Article	IF	Citations
253	Fracture risk assessment. Clinical Biochemistry, 2012, 45, 887-893.	1.9	44
254	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	21.4	1,100
255	Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Archives of Osteoporosis, 2012, 7, 67-73.	2.4	73
256	The distribution of FRAXÂ®-based probabilities in women from Japan. Journal of Bone and Mineral Metabolism, 2012, 30, 700-705.	2.7	31
257	An appendix to the 2012 IOFâ€“ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2012, 7, 25-30.	2.4	35
258	Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 209-218.	2.4	16
259	The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Archives of Osteoporosis, 2012, 7, 229-235.	2.4	28
260	Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 237-246.	2.4	30
261	Does osteoporosis therapy invalidate FRAX for fracture prediction?. Journal of Bone and Mineral Research, 2012, 27, 1243-1251.	2.8	105
262	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Journal of Bone and Mineral Research, 2012, 27, 1480-1486.	2.8	126
263	FRAX underestimates fracture risk in patients with diabetes. Journal of Bone and Mineral Research, 2012, 27, 301-308.	2.8	307
264	High fracture probability with FRAXÂ® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporosis International, 2012, 23, 391-397.	3.1	89
265	â€˜Sink or swimâ€™: an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporosis International, 2012, 23, 643-654.	3.1	47
266	Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International, 2012, 23, 75-85.	3.1	102
267	Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporosis International, 2012, 23, 991-999.	3.1	57
268	A comparative study of using non-hip bone density inputs with FRAXÂ®. Osteoporosis International, 2012, 23, 853-860.	3.1	17
269	Pitfalls in the external validation of FRAX. Osteoporosis International, 2012, 23, 423-431.	3.1	95
270	A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporosis International, 2012, 23, 907-915.	3.1	47

#	Article	IF	Citations
271	FRAXÂ® with and without Bone Mineral Density. Calcified Tissue International, 2012, 90, 1-13.	3.1	173
272	Official Positions for FRAXÂ® Clinical Regarding Biochemical Markers. Journal of Clinical Densitometry, 2011, 14, 220-222.	1.2	41
273	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAXÂ®. Journal of Clinical Densitometry, 2011, 14, 171-180.	1.2	82
274	Official Positions for FRAXÂ® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAXÂ® of the 10 Year Risk of Fracture. Journal of Clinical Densitometry, 2011, 14, 212-219.	1.2	85
275	FRAXÂ® Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. Journal of Clinical Densitometry, 2011, 14, 181-183.	1.2	11
276	Bisphosphonates in oncology. Bone, 2011, 49, 71-76.	2.9	167
277	Is FRAXÂ® a valid screening tool for fragility fracture risk assessment in HIV-positive individuals?. Journal of Infection, 2011, 63, e39-e40.	3.3	0
278	388 CAN LOW RESOLUTION DUAL ENERGY X-RAY ABSORPTIOMETRY IMAGES BE USED TO GRADE OSTEOARTHRITIS SEVERITY?. Osteoarthritis and Cartilage, 2011, 19, S179.	1.3	0
279	A FRAXÂ® model for the assessment of fracture probability in Belgium. Osteoporosis International, 2011, 22, 453-461.	3.1	53
280	Cost-effectiveness of bazedoxifene incorporating the FRAXÂ® algorithm in a European perspective. Osteoporosis International, 2011, 22, 955-965.	3.1	28
281	Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. Osteoporosis International, 2011, 22, 1411-1418.	3.1	31
282	Development and validation of a disease model for postmenopausal osteoporosis. Osteoporosis International, 2011, 22, 771-780.	3.1	17
283	Spineâ€“hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporosis International, 2011, 22, 839-847.	3.1	131
284	Construction of a FRAXÂ® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporosis International, 2011, 22, 817-827.	3.1	144
285	Fracture prediction and calibration of a Canadian FRAXÂ® tool: a population-based report from CaMos. Osteoporosis International, 2011, 22, 829-837.	3.1	160
286	A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAXÂ®. Osteoporosis International, 2011, 22, 2347-2355.	3.1	82
287	Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporosis International, 2011, 22, 2359-2364.	3.1	49
288	Evaluation of FRAX to characterise fracture risk in Poland. Osteoporosis International, 2011, 22, 2507-2512.	3.1	21

#	Article	IF	Citations
289	Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis International, 2011, 22, 809-816.	3.1	248
290	Interpretation and use of FRAX in clinical practice. Osteoporosis International, 2011, 22, 2395-2411.	3.1	450
291	Osteoporosis: burden, health care provision and opportunities in the EU. Archives of Osteoporosis, 2011, 6, 59-155.	2.4	459
292	Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Archives of Osteoporosis, 2011, 6, 179-188.	2.4	69
293	Effects of antiresorptive treatment on nonvertebral fracture outcomes. Journal of Bone and Mineral Research, 2011, 26, 2411-2418.	2.8	40
294	Use of FRAXÂ® to target BMD in women <65 years of age. Nature Reviews Endocrinology, 2011, 7, 383-384.	9.6	0
295	Prevention of bone loss and management of fracture risk in HIV-infected individuals: case studies and recommendations for different patient subgroups. Future Virology, 2011, 6, 769-782.	1.8	2
296	Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. PLoS Genetics, 2011, 7, e1001372.	3.5	233
297	Preventing osteoporotic fractures in older people. Practitioner, 2011, 255, 19-22, 2-3.	0.3	5
298	The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporosis International, 2010, 21, 339-349.	3.1	23
299	The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXÂ®. Osteoporosis International, 2010, 21, 495-505.	3.1	46
300	The effects of a FRAXÂ® revision for the USA. Osteoporosis International, 2010, 21, 35-40.	3.1	89
301	The US FRAXÂ® filter: avoiding confusion or hindering progress?. Osteoporosis International, 2010, 21, 885-885.	3.1	10
302	Development and use of FRAXÂ® in osteoporosis. Osteoporosis International, 2010, 21, 407-413.	3.1	320
303	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis, 2010, 5, 19-48.	2.4	18
304	Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. Journal of Bone and Mineral Research, 2010, 25, 2350-2358.	2.8	243
305	Lateral back pain identifies prevalent vertebral fractures in post-menopausal women: cross-sectional analysis of a primary care-based cohort. Rheumatology, 2010, 49, 505-512.	1.9	17
306	Are wrist fractures a good predictor of future fractures, and what are the implications for FRAXÂ®?. IBMS BoneKEy, 2010, 7, 254-258.	0.0	0

#	Article	IF	Citations
307	FRAXÂ® and its applications in health economicsâ€"Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone, 2010, 47, 430-437.	2.9	34
308	A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAXÂ®. Bone, 2010, 47, 729-735.	2.9	93
309	Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer, 2010, 46, 558-565.	2.8	37
310	HIV and bone disease. Archives of Biochemistry and Biophysics, 2010, 503, 66-77.	3.0	68
311	Diagnostic Thresholds for Osteoporosis in Men. , 2010, , 605-611.		3
312	Calculating fracture risk in primary care. Practitioner, 2010, 254, 7.	0.3	0
313	Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150â€‰mg and risedronate 150â€‰mg. Current Medical Research and Opinion, 2009, 25, 2951-2960.	1.9	8
314	The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture. Medical Decision Making, 2009, 29, 678-689.	2.4	19
315	How to decide who to treat. Best Practice and Research in Clinical Rheumatology, 2009, 23, 711-726.	3.3	23
316	From relative risk to absolute fracture risk calculation: The FRAX algorithm. Current Osteoporosis Reports, 2009, 7, 77-83.	3.6	130
317	Ten-year fracture probability identifies women who will benefit from clodronate therapyâ€"additional results from a double-blind, placebo-controlled randomised study. Osteoporosis International, 2009, 20, 811-817.	3.1	134
318	BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporosis International, 2009, 20, 1675-1682.	3.1	121
319	Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporosis International, 2009, 20, 2055-2061.	3.1	34
320	Use of DXA-Based Structural Engineering Models of the Proximal Femur to Discriminate Hip Fracture. Journal of Bone and Mineral Research, 2009, 24, 33-42.	2.8	61
321	Assessment of fracture risk. European Journal of Radiology, 2009, 71, 392-397.	2.6	109
322	FRAXÂ® and its applications to clinical practice. Bone, 2009, 44, 734-743.	2.9	605
323	Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAXÂ®. Bone, 2009, 44, 1049-1054.	2.9	147
324	Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone, 2009, 45, 1053-1058.	2.9	149

#	Article	IF	Citations
325	Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 2009, 62, 105-108.	2.4	346
326	Approaches to the targeting of treatment for osteoporosis. Nature Reviews Rheumatology, 2009, 5, 425-431.	8.0	39
327	Abdominal Aortic Calcification Detected on Lateral Spine Images From a Bone Densitometer Predicts Incident Myocardial Infarction or Stroke in Older Women. Journal of Bone and Mineral Research, 2008, 23, 409-416.	2.8	108
328	Expressing fracture risk. Osteoporosis International, 2008, 19, 593-594.	3.1	3
329	FRAXâ„¢ and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 2008, 19, 385-397.	3.1	2,017
330	Case finding for the management of osteoporosis with FRAXÂ®â€"assessment and intervention thresholds for the UK. Osteoporosis International, 2008, 19, 1395-1408.	3.1	520
331	Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. Journal of Bone and Mineral Research, 2008, 23, 1591-1600.	2.8	241
332	Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis. Journal of Bone and Mineral Research, 2008, 23, 1561-1568.	2.8	89
333	A reference standard for the description of osteoporosis. Bone, 2008, 42, 467-475.	2.9	929
334	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews, 2008, 34, S3-S18.	7.7	209
335	Shape, Structural Properties, and Cortical Stability Along the Femoral Neck: A Study Using Clinical QCT. Journal of Clinical Densitometry, 2008, 11, 373-382.	1.2	11
336	Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 2008, 14, 6-12.	1.6	61
337	Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 852-860.	3.6	216
338	Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference. Clinical Cancer Research, 2008, 14, 6387-6395.	7.0	64
339	Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients. Journal of International Medical Research, 2008, 36, 400-413.	1.0	12
340	FRAXâ„¢ and the assessment of fracture probability: An introduction. IBMS BoneKEy, 2008, 5, 114-117.	0.0	0
341	FRAX I OTsENKA RISKA PERELOMA U MUZhChIN I ZhENShchIN V VELIKOBRITANII. Osteoporosis and Bone Diseases, 2008, 11, 38-44.	1.4	0
342	Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clinical Cancer Research, 2007, 13, 5406-5410.	7.0	68

#	Article	IF	Citations
343	The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006. Annals of Oncology, 2007, 18, 393.	1.2	1
344	Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. European Journal of Cancer, 2007, 43, 2523-2531.	2.8	85
345	Protective effect of Î² blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 2007, 40, 1209-1216.	2.9	129
346	The Use of Bone Markers in a 6-Week Study to Assess the Efficacy of Oral Clodronate in Patients with Metastatic Bone Disease. Calcified Tissue International, 2007, 81, 341-351.	3.1	20
347	Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporosis International, 2007, 18, 35-43.	3.1	52
348	The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis International, 2007, 18, 1033-1046.	3.1	1,017
349	Estimates of fracture probability in Denmark. Osteoporosis International, 2007, 18, 1141-1143.	3.1	0
350	Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, 2007, 11, iii-iv, ix-xi, 1-231.	2.8	124
351	Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research, 2006, 8, R13.	5.0	243
352	Effects of third-generation aromatase inhibitors on bone. European Journal of Cancer, 2006, 42, 1044-1051.	2.8	78
353	Cost Implications of Bisphosphonates. , 2006, , 415-426.		0
354	Prevention of Bone Loss. , 2006, , 399-414.		0
355	Current status and future prospects in the management of bone disease. Future Rheumatology, 2006, 1, 289-291.	0.2	0
356	Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study. Journal of Bone and Mineral Research, 2006, 22, 135-141.	2.8	180
357	Ileum resection is the most predictive factor for osteoporosis in patients with Crohnâ€™s disease. Osteoporosis International, 2006, 17, 535-542.	3.1	33
358	Modified Calcaneal Index: A New Screening Tool for Osteoporosis Based on Plain Radiographs of the Calcaneum. Journal of Orthopaedic Surgery, 2005, 13, 27-33.	1.0	5
359	Serum Retinoids and Î²-Carotene as Predictors of Hip and Other Fractures in Elderly Women. Journal of Bone and Mineral Research, 2005, 20, 913-920.	2.8	64
360	Case-Finding for Adult Celiac Disease in Patients with Reduced Bone Mineral Density. Digestive Diseases and Sciences, 2005, 50, 587-592.	2.3	28

#	Article	IF	Citations
361	Smoking and fracture risk: a meta-analysis. Osteoporosis International, 2005, 16, 155-162.	3.1	755
362	A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporosis International, 2005, 16, 799-804.	3.1	123
363	Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporosis International, 2005, 16, 1330-1338.	3.1	1,292
364	Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Current Medical Research and Opinion, 2005, 21, 805-815.	1.9	15
365	The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treatment Reviews, 2005, 31, 115-142.	7.7	60
366	The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fracturesâ€"An open label study. Bone, 2005, 36, 47-51.	2.9	36
367	Vertebral Deformities in Rheumatoid Arthritis. Archives of Internal Medicine, 2004, 164, 420.	3.8	129
368	Global variations in peak bone mass as studied by dual-energy X-ray absorptiometry. Journal of Radioanalytical and Nuclear Chemistry, 2004, 259, 341-345.	1.5	2
369	Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study. Journal of Bone and Mineral Research, 2004, 19, 728-736.	2.8	114
370	A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. Journal of Bone and Mineral Research, 2004, 19, 893-899.	2.8	666
371	Risk Factors for Incident Vertebral Fractures in Men and Women: The Rotterdam Study. Journal of Bone and Mineral Research, 2004, 19, 1172-1180.	2.8	160
372	Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis. Journal of Bone and Mineral Research, 2004, 19, 906-913.	2.8	130
373	A meta-analysis of previous fracture and subsequent fracture risk. Bone, 2004, 35, 375-382.	2.9	1,052
374	A family history of fracture and fracture risk: a meta-analysis. Bone, 2004, 35, 1029-1037.	2.9	344
375	An Age- and Sex-Controlled Matched Pair Analysis of T Scores in Ethnic Indians with Hip Fractures. Journal of Orthopaedic Surgery, 2004, 12, 133-133.	1.0	0
376	Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Oncology, 2004, 22, 528-528.	1.6	6
377	A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 2004, 22, 8056-8056.	1.6	2
378	Management of bone disease. , 2004, , 319-CP8.		0

#	Article	IF	Citations
379	Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients. Journal of Bone and Mineral Research, 2003, 18, 1254-1260.	2.8	220
380	Medical Management of Hypercalcemia. Calcified Tissue International, 2003, 74, 1-11.	3.1	23
381	Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. Drug Safety, 2003, 26, 661-671.	3.2	45
382	Oral clodronate as treatment of osteogenesis imperfecta. Archives of Disease in Childhood, 2003, 88, 945-945.	1.9	5
383	Osteoporosis management by geriatricians in the UK. Age and Ageing, 2003, 32, 553-553.	1.6	3
384	Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density. Postgraduate Medical Journal, 2003, 79, 581-584.	1.8	7
385	A primary care cross-sectional study of undiagnosed adult coeliac disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 407-413.	1.6	237
386	Clodronate in the management of breast cancer and multiple myeloma. Ortopedia Traumatologia Rehabilitacja, 2003, 5, 227-33.	0.3	1
387	Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3219-3224.	1.6	362
388	Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis. Sarcoma, 2002, 6, 131-133.	1.3	1
389	The Incidence of Vertebral Fractures in Men and Women: The Rotterdam Study. Journal of Bone and Mineral Research, 2002, 17, 1051-1056.	2.8	265
390	Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3-Year Randomized Placebo-Controlled Clinical Trial With a 2-Year Open Extension. Journal of Bone and Mineral Research, 2002, 17, 1057-1064.	2.8	69
391	Neurological Complications of Paget's Disease. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 135-144.	0.8	11
392	Contribution of calcium and other dietary components to global variations in bone mineral density in young adults. Food and Nutrition Bulletin, 2002, 23, 180-4.	1.4	4
393	The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma. Drugs, 2001, 61, 1253-1274.	10.9	36
394	Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone, 2001, 28, 310-315.	2.9	47
395	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. Calcified Tissue International, 2001, 68, 348-351.	3.1	36
396	Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology, 2001, 113, 1035-1043.	2.5	160

#	Article	IF	Citations
397	Prevalence and Causes of Low Bone Density and Fractures in Kidney Transplant Patients*. Journal of Bone and Mineral Research, 2001, 16, 1863-1870.	2.8	89
398	Atypical familial Pagetâ€™s disease of bone. Joint Bone Spine, 2001, 68, 257-261.	1.6	4
399	Bisphosphonates in multiple myeloma. Cancer, 2000, 88, 3022-3032.	4.1	46
400	Metacarpal Morphometry Using a Semi-automated Technique in the Assessment of Osteoporosis and Vertebral Fracture Risk. Osteoporosis International, 2000, 11, 953-958.	3.1	26
401	Is a Calculated Total Hip BMD of Clinical Use?. Osteoporosis International, 2000, 11, 368-371.	3.1	7
402	Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. Maturitas, 2000, 37, 75-81.	2.4	39
403	Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. Bone, 2000, 26, 525-528.	2.9	15
404	Vertebral osteophytosis and vertebral deformities in an elderly population sample. Wiener Klinische Wochenschrift, 2000, 112, 407-12.	1.9	10
405	Effect of calcitonin on vertebral and other fractures. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 143-150.	0.5	50
406	Economic impact of using clodronate in the management of patients with multiple myeloma. British Journal of Haematology, 1999, 104, 358-364.	2.5	40
407	A high incidence of vertebral fracture in women with breast cancer. British Journal of Cancer, 1999, 79, 1179-1181.	6.4	243
408	Clinical Assessment of Bone Mass, Quality and Architecture. Osteoporosis International, 1999, 9, S24-S28.	3.1	13
409	Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteoporosis International, 1999, 10, 150-160.	3.1	346
410	Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go. Journal of Bone and Mineral Research, 1999, 14, 74-78.	2.8	12
411	The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. Journal of Rheumatology, 1999, 26, 842-8.	2.0	119
412	Short-term Reproducibility of Proximal Femur Bone Mineral Density in the Elderly. Calcified Tissue International, 1998, 63, 296-299.	3.1	25
413	A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 1998, 100, 317-325.	2.5	292
414	Risk factors in osteoporosis. Maturitas, 1998, 30, 229-233.	2.4	54

#	Article	IF	Citations
415	An unusual cause of pulmonary hypertension and right heart failure.. Postgraduate Medical Journal, 1998, 74, 697-698.	1.8	1
416	Oral Clodronate and Reduction in Loss of Bone Mineral Density in Women With Operable Primary Breast Cancer. Journal of the National Cancer Institute, 1998, 90, 704-708.	6.3	159
417	Use of Bisphosphonates in the Treatment of Multiple Myeloma. Hematology, 1998, 3, 291-298.	1.5	1
418	Alendronate in the treatment of Paget's disease of bone. Bone, 1997, 20, 263-271.	2.9	44
419	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 1997, 12, 1700-1707.	2.8	247
420	Preliminary study on relationship between vertebral fracture and aortic calcification in postmenopausal women. Journal of Bone and Mineral Metabolism, 1997, 15, 218-222.	2.7	3
421	Treatment of osteoporosis with vitamin D. Osteoporosis International, 1997, 7, 140-146.	3.1	13
422	Vitamin D and analogues in renal bone disease and implications for osteoporosis. Osteoporosis International, 1997, 7, 179-183.	3.1	5
423	Bone turnover and biochemical markers in malignancy. Cancer, 1997, 80, 1538-1545.	4.1	63
424	Clodronate. Cancer, 1997, 80, 1691-1695.	4.1	15
425	Bone turnover and biochemical markers in malignancy. Cancer, 1997, 80, 1538-1545.	4.1	16
426	Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone, 1996, 19, 663-667.	2.9	218
427	Duration of response with oral clodronate in Paget's disease of bone. Bone, 1996, 18, 185-190.	2.9	160
428	Paget's disease of bone and unvaccinated dogs. Bone, 1996, 19, 47-50.	2.9	46
429	Evaluation of the risk of hip fracture. Bone, 1996, 18, S127-S132.	2.9	57
430	Clodronate and osteoporosis. Maturitas, 1996, 23, S81-S86.	2.4	14
431	Assessment of osteopenia from spine radiographs using two different methods: the Chingford study. British Journal of Radiology, 1996, 69, 451-456.	2.2	15
432	A precise method for the assessment of tibial ultrasound velocity. Osteoporosis International, 1996, 6, 1-7.	3.1	66

#	Article	IF	Citations
433	Comparison of three intravenous regimens of clodronate in paget disease of bone. Journal of Bone and Mineral Research, 1996, 11, 178-182.	2.8	26
434	Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.. Journal of Clinical Oncology, 1995, 13, 929-934.	1.6	59
435	Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone, 1995, 17, 517-520.	2.9	32
436	The effects of intravenous alendronate in Paget's disease of bone. Journal of Bone and Mineral Research, 1995, 10, 1094-1100.	2.8	27
437	Events per person year. BMJ: British Medical Journal, 1995, 310, 1469-1469.	2.3	3
438	Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. The Canadian Journal of Oncology, 1995, 5 Suppl 1, 54-7.	0.1	1
439	WR-2721 and hypocalcemia.. Journal of Clinical Oncology, 1994, 12, 232-232.	1.6	1
440	CONSEQUENCES OF NEOPLASIA INDUCED BONE-RESORPTION AND THE USE OF CLODRONATE (REVIEW). International Journal of Oncology, 1994, 5, 713-31.	3.3	8
441	Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis.. Annals of the Rheumatic Diseases, 1994, 53, 117-121.	0.9	176
442	Letters. Osteoporosis International, 1994, 4, 117-119.	3.1	10
443	Effects of intravenous dichloromethylene bisphosphonate (CL2MBP) in the treatment of Paget's disease of bone. Seminars in Arthritis and Rheumatism, 1994, 23, 270.	3.4	1
444	Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease. Seminars in Arthritis and Rheumatism, 1994, 23, 271.	3.4	4
445	Tumour induced hypercalcaemia: A case for active treatment. Clinical Oncology, 1994, 6, 172-176.	1.4	10
446	The effect of alendronate on renal tubular reabsorption of phosphate. Bone and Mineral, 1994, 27, 51-56.	1.9	7
447	Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment. Drug Investigation, 1994, 7, 26-33.	0.6	16
448	Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). British Journal of Cancer, 1994, 69, 914-917.	6.4	30
449	Intra-Individual Variation in Fasting Urinary Calcium- and Hydroxyproline-Creatinine Ratios Measured in Metabolic Bone Clinic Patients as Both Outpatients and Inpatients. Annals of Clinical Biochemistry, 1994, 31, 272-276.	1.6	39
450	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer, 1993, 67, 560-563.	6.4	77

#	Article	IF	Citations
451	Distinction between Focally Accelerated Bone Formation and Osteomalacia in Carcinoma of Prostate Metastasised to Bone. British Journal of Urology, 1993, 72, 98-103.	0.1	12
452	Rationale for the use of clodronate in osteoporosis. Osteoporosis International, 1993, 3, 23-28.	3.1	26
453	The assessment of vertebral deformity: A method for use in population studies and clinical trials. Osteoporosis International, 1993, 3, 138-147.	3.1	503
454	Treatment of osteoporosis. Journal of Bone and Mineral Metabolism, 1993, 11, S17-S24.	2.7	0
455	Risk of vertebral fracture in women with rheumatoid arthritis.. BMJ: British Medical Journal, 1993, 306, 558-558.	2.3	204
456	Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.. Journal of Clinical Oncology, 1993, 11, 59-65.	1.6	563
457	Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The chingford study. Journal of Bone and Mineral Research, 1993, 8, 817-822.	2.8	121
458	Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate). Drug Safety, 1992, 7, 162-165.	3.2	27
459	Effective treatment of malignant hypercalcaemia using a single intravenous infusion of clodronate. Bone and Mineral, 1992, 17, S28.	1.9	1
460	Osteoporotic fractures: An unusual presentation of haemochromatosis. Bone, 1992, 13, 431-433.	2.9	41
461	Epidemiology of vertebral osteoporosis. Bone, 1992, 13, S1-S10.	2.9	126
462	Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology, 1992, 49, 192-198.	2.2	172
463	Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. Bone, 1991, 12, 17-20.	2.9	29
464	Treatment of skeletal disease in breast cancer with clodronate. Bone, 1991, 12, S25-S30.	2.9	27
465	Rationale for the use of bisphosphonates in bone metastases. Bone, 1991, 12, S13-S18.	2.9	47
466	Between Isolation and Intrusion: The Patient Self-Determination Act. Journal of Law, Medicine, and Ethics, 1991, 19, 80-82.	0.6	8
467	Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface. Clinical Science, 1991, 81, 543-549.	0.0	12
468	Treatment of Pagetâ€™s Disease with the New Bisphosphonates. , 1991, , 112-134.		4

#	Article	IF	Citations
469	A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clinical Science, 1990, 78, 215-219.	4.3	29
470	Assessment of broadband ultrasound attenuation in the os calcis in vitro. Clinical Science, 1990, 78, 221-225.	4.3	109
471	Broadband ultrasound attenuation in the os calcis: relationship to bone mineral at other skeletal sites. Clinical Science, 1990, 78, 227-233.	4.3	108
472	The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1. Progress in Basic and Clinical Pharmacology, 1990, 4, 89-136.	0.1	30
473	Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate. Journal of Bone and Mineral Research, 1990, 5, 483-491.	2.8	69
474	Effects of Clodronate in Severe Hyperparathyroid Bone Disease in Chronic Renal Failure. Nephron, 1990, 56, 6-12.	1.8	21
475	Use of diphosphonates in hypercalcaemia due to malignancy. Lancet, The, 1990, 335, 170-1.	13.7	11
476	Pseudohyperphosphataemia in multiple myeloma.. BMJ: British Medical Journal, 1989, 299, 1381-1382.	2.3	20
477	Phosphate binding efficiency of a polyuronic acid in normal subjects. Nephrology Dialysis Transplantation, 1989, 4, 829-30.	0.7	0
478	Calcium metabolism and myeloma and the treatment of hypercalcemia. Hematological Oncology, 1988, 6, 115-117.	1.7	1
479	Diphosphonates and phosphate homoeostasis in man. Clinical Science, 1988, 74, 607-612.	4.3	32
480	Treating Paget's disease.. BMJ: British Medical Journal, 1987, 294, 1612-1613.	2.3	2
481	Effects of intravenous etidronate disodium on skeletal and calcium metabolism. American Journal of Medicine, 1987, 82, 55-70.	1.5	64
482	TRANSIENT TASTE-LOSS DURING TREATMENT WITH ETIDRONATE. Lancet, The, 1987, 330, 637.	13.7	12
483	Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone, 1987, 8 Suppl 1, S35-41.	2.9	18
484	Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone, 1987, 8 Suppl 1, S43-51.	2.9	12
485	Clodronate in the medical management of hyperparathyroidism. Bone, 1987, 8 Suppl 1, S69-77.	2.9	11
486	Population screening for fracture risk in postmenopausal women â€" a logical step in reducing the osteoporotic fracture burden?. Osteoporosis International, 0, , .	3.1	2